# How tirzepatide works: GIP and GLP-1, explained

Tirzepatide acts on two hormone receptors involved in appetite and glucose regulation. Here is what that means in plain English.

Canonical: https://velri.co/blog/tirzepatide-dual-action-gip-glp1-plain-english-stalled-ex-athlete
Publisher: Velri (https://velri.co/about)
Published: 2026-07-25
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

Tirzepatide activates two types of receptors: GIP and GLP-1. These receptors respond to signals involved in appetite and blood glucose regulation. The medication is sometimes described as having a dual action because it works through both.[1]

That describes its biology. It does not mean twice the weight loss or twice the benefit for every person.

## What the two signals do

GIP stands for glucose-dependent insulinotropic polypeptide. GLP-1 stands for glucagon-like peptide-1. Both are hormones the body makes, and tirzepatide is designed to activate their receptors.[1]

According to the approved prescribing information, tirzepatide increases insulin secretion in a glucose-dependent way, reduces glucagon secretion, and improves insulin sensitivity. In simpler terms, it affects how the body responds to and manages glucose.[1]

It also reduces calorie intake through effects on appetite. Its action in weight management therefore includes an effect on appetite.[1]

## Where digestion fits

Tirzepatide delays stomach emptying. That effect is largest after the first dose and diminishes over time.[1] It is one part of the medication's action, not a complete explanation for every change in hunger, fullness, or digestion.

Nausea, vomiting, diarrhea, and constipation are among the common adverse reactions.[1] Stronger digestive symptoms are not evidence that someone is getting a better result.

## What the mechanism cannot predict

Knowing the receptor targets cannot tell an individual how much weight they will lose, how quickly it will happen, or whether they will tolerate the medication. Those questions require evaluation and follow-up.

Research and prescribing information for an FDA-approved tirzepatide product also do not establish that a compounded formulation has the same safety, effectiveness, or quality. Compounded drugs are not FDA-approved.[2]

## Sources
[1] DailyMed - ZEPBOUND- tirzepatide injection, solution
ZEPBOUND- tirzepatide injection, solution
ZEPBOUND KWIKPEN- tirzepatide injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
[2] Compounding and the FDA: Questions and Answers | FDA. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support